Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases

Published:2022-11-14 Issue:1 Volume:33 Page:58-65
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Huo Cecilia W.,Gunadasa Indika,Gkolia Panagiota,Shackleton Mark,Hunn Martin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference29 articles.

1. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.;Robert;Lancet Oncol,2019

2. Determinants of outcome in melanoma patients with cerebral metastases.;Fife;J Clin Oncol: Off J Am Soc Clin Oncol,2004

3. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.;Long;Lancet Oncol,2018

4. Combined nivolumab and ipilimumab in melanoma metastatic to the Brain.;Tawbi;N Engl J Med,2018

5. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking.;Taggart;Proc Natl Acad Sci USA,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP